You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI

    SBC: VENTRIX INCORPORATED            Topic: NHLBI

    Summary Heart failure post-myocardial infarction (MI) continues to be the leading cause of death in the U.S. Each year it is estimated that ~550K Americans will have a new MI, and ~200K will have a recurrent MI, leading to a large body of patients suffering from heart failure. These staggering statistics necessitate the development of new therapies for patients with ischemic cardiomyopathy. Tissue ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

    SBC: KINTARA THERAPEUTICS INC            Topic: NCI

    ABSTRACT Cutaneous metastatic breast cancer (CMBC) develops in up to 24% of patients with metastatic breast cancer. Systemic therapy often has limited efficacy in such cases, and surgery and radiotherapy offer only transient relief and their use may be limited in the CMBC population due to the side-effects involved and the extent of cutaneous lesions. CMBC can cause infection, bleeding, malodor an ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Minimally invasive access and aspiration of circulating lymphocytes from the thoracic duct

    SBC: LXS, LLC            Topic: 300

    Building on a half-century of innovation in transvascular access and ultrasound image guidance, LXS has developed a novel catheter device and venous access procedure to cannulate and aspirate the thoracic duct under ultrasound guidance. The company has successfully completed Phase I and II of the NIH’s SBIR program and is applying for a Commercialization Readiness Pilot (CRP) award to complete d ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of World's First Fully Human Broad Spectrum Anti-Snake Venom

    SBC: Centivax Inc            Topic: NIAID

    ABSTRACT Snakebite envenoming poses a global risk to human health. For over 125 years, antivenoms have consisted of animal-derived polyclonal serum immunoglobulin G (IgG). In recent decades, IgG digested into antigen-binding fragments Fab(2) has been found to reduce some of the most severe side-effects of non-human antivenom. These antivenoms are obtained by immunizing horses or sheep with individ ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance

    SBC: Enable Biosciences Inc.            Topic: NIDDK

    Project Summary Type 1 diabetes, a chronic autoimmune disorder that affects millions of Americans is characterized by the progressive destruction of the insulin-producing islet cells of the pancreas, resulting in life-long dependency on insulin therapy. Many people with type 1 diabetes are diagnosed with life-threatening diabetic ketoacidosis and develop a panoply of perilous complications affecti ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A Personalized Digital Intervention Program to Reduce Exposure to Endocrine Disrupting Chemicals among a Child-Bearing Age Cohort

    SBC: MILLION MARKER WELLNESS INC            Topic: 142

    Project Summary/AbstractExposures to endocrine disrupting chemicals (EDCs) have been linked to chronic diseases and conditions including breast cancer, metabolic syndrome, diabetes and infertility. Timing of exposure, especially during pregnancy, may have a lifelong impact on the fetus. Tools and services are urgently needed to allow individuals to learn about their personal EDC exposures and how ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme

    SBC: SONALASENSE, INC.            Topic: 102

    PROJECT SUMMARY Glioblastoma multiforme (GBM) is a rare and deadly cancer. First line treatment for GBM includes maximal surgical resection with radiotherapy administered post-surgery, and concomitant administration of adjuvant temozolomide. Tumor recurrence is nearly inevitable due to the microscopic, infiltrating cells that are found centimeters from the margin of visible tumor mass. There is cu ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A State-of-the-Art Automatic Speech Recognition and Conversational Platform to Enable Socially Assistive Robots for Persons with Alzheimer's Disease and Related Dementias

    SBC: CARE.COACH CORPORATION            Topic: R

    ABSTRACT This commercialization readiness pilot (CRP) by care.coach corporation (Millbrae, CA) requests funds for late- stage research and development and technical assistance for a conversational technology driven by artificial intelligence (AI) that was developed with and for older adults, especially those aging with Alzheimer’s disease and related dementias (ADRD). Past work has resulted in a ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy

    SBC: OrsoBio, Inc.            Topic: 200

    TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy AbstractPatients with lipodystrophies exhibit hypertriglyceridemia, severe insulin resistance, type 2 diabetes mellitus, and nonalcoholic steatohepatitis (NASH), and have limited effective treatment options. Lipodystrophy is characterized by the ectopic acc ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a novel, regenerative therapy to reverse synapse loss in Alzheimer's Disease

    SBC: SPINOGENIX, INC.            Topic: R

    Project Summary/AbstractThe mission of the SBIR program is to “encourage domestic small businesses to engage in Federal Research/Research and Development (R/RandD) that has the potential for commercialization.” A mission of the NIA is to “support research on Alzheimer’s disease, and promote research on the etiology, treatment, and diagnosis of AD”. The proposed development program is nec ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government